Monday is not blue!

-
Monday is not blue🤭

PHI wishes you a happy day ahead!😉


For university-industry project collaboration/ internship inquiry/ job recruitment/ anything you need us to liaise with, contact us:

Pejabat Hubungan Industri (Industry Liaison Office) UKM
Levell 5, Chancellery Building,
43600 UKM, Bangi, Selangor
MALAYSIA.
Tel: +603-8921 4658 / 4657
Email: phi@ukm.edu.my
Blog: http://phihejim.blogspot.com/
Facebook: https://www.facebook.com/phi.ukm
Instagram: phi_ukm

Comments

Post a Comment

MUST-READS

ICT Mumbai towards getting top 100 in the world over next 10 years

-
Q&A session with prof. GD Yadav! 😁 Prof. GD Yadav, Vice Chancellor, Institute of Chemical Technology (ICT) Mumbai, aims to develop the institution towards getting it among the top 100 in the world over next 10 years. In this interview with Careers360, Prof Yadav talks about the role of teaching standards in improving the quality and ranking of an institution, the scope of industry collaboration and benefits that can come along engagement with international faculties and global universities... Read the Q&A in https://news.careers360.com/my-vision-make-ict-one-top-100-institutes-world-10-years
Read more

Taklimat Penggunaan ICESYS

-
Image
Salam semua..sedikit penerangan mengenai sistem ICESYS; Apakah rekod yang dimasukkan dalam ICESYS? ia adalah KHIDMAT dan KETERLIBATAN Bagaimanakah cara nak masukkan rekod dan proses di dalam sistem ICESYS? Apakah contoh projek keterlibatan dan bagaimana nak pilih kategorinya? Hasrat HEJIM untuk tahun 2013 dan penambahbaikkan sistem mengikut kriteria kenaikan pangkat; post by: Syaz 
Read more

Collaboration to Develop Novel Class of Drug Conjugate

-
Collaboration to Develop Novel Class of Drug Conjugate😎 "The Affimer-drug conjugate circulates as a single molecule, in which the conjugated drug is inert, until it encounters enzymes selectively expressed in tumours, where the drug is released and through its mechanism of action is designed to turn immunologically “cold” tumours “hot” and receptive to immunotherapy. It is our expectation that this will increase the percentage of responsive patients dramatically and in doing so, it will make a meaningful difference to the lives of a great many cancer patients.” https://www.labmate-online.com/news/news-and-views/5/avacta-group/collaboration-to-develop-novel-class-of-drug-conjugate/46762
Read more